Top Markets
#1 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.38%
#2 Victoria VR Victoria VR +11.93%
#3 Movement Movement +11.39%
#4 Palladium Network Palladium Network +9.28%
#5 DMT-NAT DMT-NAT +6.25%
#6 Cryptopia Cryptopia +4.73%
#7 Pons Pons +4.23%
#8 GRVT Token GRVT Token +3.85%
#9 MarsCoin MarsCoin +3.69%
#10 COTI COTI +3.65%
Coin of the day
FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock)
Settings
Language
ENGLISH
Currency
USD
Theme
Novo Nordisk A/S Novo Nordisk A/S

Novo Nordisk A/S

NOVO-B
Rank in Stocks #88
Novo Nordisk A/S operates as a global healthcare enterprise, dedicated to the... Novo Nordisk A/S operates as a global healthcare enterprise, dedicated to the innovation, development, production, and commercialization of pharmaceutical solutions. Its business is primarily divided into two key segments: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care segment offers a comprehensive portfolio of treatments for diabetes (including insulins, GLP-1 analogues, oral antidiabetic agents, and related delivery systems), obesity management, glucagon, medical needles, and other chronic conditions. The Rare Disease segment provides specialized medications for haemophilia, various blood disorders, endocrine imbalances, growth hormone deficiencies, and hormone replacement therapy. Additionally, the company engages in strategic alliances, including a partnership with Gilead Sciences, Inc., and conducts research focused on identifying cell-specific carriers for nucleic acid-based therapies. Established in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.
Share Price
$47.55
Last synced: 2026-08-12
Market Cap
$211.25B
Change (1 day)
-2.51%
Change (1 year)
-6.99%
Country
DK
Trade Novo Nordisk A/S (NOVO-B)

Category

Healthcare
Revenue for Novo Nordisk A/S (NOVO-B)
Revenue in Dec 2025 TTM: $48.55B
According to Novo Nordisk A/S latest financial reports the company's current revenue (TTM) is $48.55B. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Novo Nordisk A/S from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Eli Lilly and Company Eli Lilly and Company
Eli Lilly and Company
LLY.US
 $79.67B 64.10%
US
Johnson & Johnson Johnson & Johnson
Johnson & Johnson
JNJ.US
 $97.93B 101.72%
US
AbbVie Inc. AbbVie Inc.
AbbVie Inc.
ABBV.US
 $64.39B 32.62%
US
Roche Holding AG Roche Holding AG
Roche Holding AG
RO.SW
 $77.52B 59.67%
CH
Merck & Co., Inc. Merck & Co., Inc.
Merck & Co., Inc.
MRK.US
 $66.40B 36.77%
US